What if we could predict whether a drug will work, before it ever reaches a patient?

This week, in another episode of Leading Beyond the Lab, we host a co-guest episode featuring Nik Sharma, CEO & Co-Founder of BioCortex, a trained neurologist with years of experience spanning clinical medicine, ALS research, academia (Cambridge, NIH) and more. And Muhannad Alomari, CTO & Co-Founder, with over a decade of experience spanning aerospace engineering, AI leadership and physics-based systems modelling.

In this episode, the duo covers:

• Why bacteria inside tumours may explain clinical trial variability, how “in silico bridge trials” could reshape oncology development, and how BioCortex plans to translate that science into commercial inflection points, global licensing models, and long-term value creation without taking traditional pipeline risk.
• From partnerships with CD BioPharma, they explain how global clinical strategy, particularly leveraging innovation and trial infrastructure emerging from China, is reshaping how oncology assets are advanced and positioned for global success.
• They also discuss investor backing from Edward Kliphuis from Sofinnova, Hussein Kanji from Hoxton Ventures and Draper Associates, and how capital discipline combined with deep-tech engineering principles (inspired by Rolls-Royce and even NASA) is shaping a new model for oncology drug development.
• They also reflect on visiting leading oncology centres in China alongside HSBC and AstraZeneca, highlighting the sheer scale and speed of patient recruitment, momentum that was clearly visible in multiple back-to-back presentations at ASCO, signalling a structural shift in global cancer innovation.

This is a conversation about speed, probability, biology, engineering, and ultimately, time. Because for patients, time is everything.

To listen to (or watch) the full episode, search “Leading Beyond the Lab BioCorteX” on wherever you get your podcasts, or click on the first link in the comments below.

Hosted on Acast. See acast.com/privacy for more information.

This week, in another episode of Leading Beyond the Lab, Lawrence Rose sits down with Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics, one of the most quietly compelling stories in cancer immunotherapy today.

With over 30 years of experience spanning academic medicine, clinical immunology, rheumatology, oncology, and global pharmaceutical leadership, Paul Peter brings a rare clinician-scientist perspective to biotech leadership. Prior to Candel, he served as Chief Immunology Officer and Global Head of Development at GSK (led by Luke Miels) , where he helped shape immunology and oncology strategy at scale. Paul Peter is also founder and previous chair of the dept of clinical immunology and rheumatology at Amsterdam UMC.

In this episode, Paul Peter covers:

- The mission behind Candel Therapeutics and why viral immunotherapy represents a fundamentally new modality, shifting the goal from helping patients live longer with cancer to helping them live without cancer.

- Why Candel’s lead programs (including CAN-2409) are gaining serious scientific credibility, supported by leaders such as Nobel laureate James P. Allison and the "father of CAR-T cell therapy" Carl June, and how this external validation is changing industry and investor perception.

- Lessons from past paradigm shifts in medicine, drawing on his early academic work at Leiden University, where once-dismissed antibody therapies later became standard of care, a parallel to today’s scepticism around viral immunotherapy.

- How leadership, culture, and decision-making drive biotech success, shaped by his experience building teams in academia, transforming R&D at GSK, and learning large-scale leadership from mentors like Lord Patrick Vallance.

- Why flexible operating models matter in biotech, including Candel’s approach to commercialisation through partners such as IDEA Pharma (led by Mike Rea) and Globe Life Sciences (Jonathon Mitchell), and cautionary lessons from companies like Oncorus and Replimune.

Be sure to check out this episode to hear how Paul-Peter Tak is helping redefine what’s possible in cancer immunotherapy - and what it takes to lead beyond the lab.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Youtube: https://www.youtube.com/@life_sciences

Website: https://arto-talent.com

Paul Peter Tak

CEO at Candel Therapeutics

LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

01:50 Candel's Mission

19:51 The US Promising Future for Candel

35:44 Culture at Candel

40:44 Paul Peter's Motivations as CEO

Hosted on Acast. See acast.com/privacy for more information.

This week on Leading Beyond the Lab, we sit down with @Edward Kliphuis, Partner at @Sofinnova Partners, one of Europe’s leading life-sciences venture capital firms.

With over 20 years of experience spanning venture capital, digital health, tech-bio investing, and global life-sciences strategy, Edward has been at the forefront of investing where biology, computation, and healthcare collide.

In this episode, Edward covers:

- What’s genuinely different about AI in drug discovery and digital medicine today, and how collapsing healthcare costs could unlock a $10 trillion opportunity by reshaping long-term global supply–demand dynamics.

- Edward explains how @Excelsior, backed by Sofinnova Partners, @Khosla Ventures and @Deerfield Management, and led by @Mike Foley, is using an AI-driven, modular chemistry platform, originating from @Marty Burke at the @University of Illinois, to create entirely new, de novo small-molecule drugs.

- Why the US pharma & tech landscape may resemble a bubble, or a once-in-a-generation inflection point

- He talks about @Latent Labs, (led by @Simon Kohl) a Sofinnova-backed company designing entirely new proteins that do not exist in nature, unlocking new therapeutic possibilities.

- Edward outlines Sofinnova’s investment in @Bioptimus and discusses @Moon Surgical, exploring how AI and robotics are improving drug discovery and augmenting clinicians in complex procedures.

- Edward reflects on the broader AI landscape, referencing an @HSBC investment banking report questioning the long-term economics underpinning large AI models such as @OpenAI, before highlighting comments from @Geoffrey Hinton on the scalability limits of current AI architectures.

From AI-driven drug discovery and robotics in surgery, to healthcare economics, venture capital philosophy, and Europe vs the US innovation gap, this is a deep, unfiltered look at where life sciences is heading next.

To listen to (or watch) the full episode, search "Leading Beyond The Lab Edward Kliphuis" on your preferred streaming platform, or click on the first link in the comments below!

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Youtube: https://www.youtube.com/@life_sciences

Website: https://arto-talent.com

Edward Kliphuis

Partner at Sofinnova Partners

LinkedIn: https://www.linkedin.com/in/ekliphuis/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Sofinnovas Partner's Investments

17:41 The US Pharma "Bubble" & AI

28:02 Investing in the Right CEO / Company

Hosted on Acast. See acast.com/privacy for more information.

This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development.

A physician by training, Amit has built his career across large pharma and early stage biotech, including experience at Bristol Myers Squibb and Biogen, working on programmes ranging from rare disease to neurodegeneration. He is also a visible advocate for authenticity and inclusion within the life sciences industry.

In this episode, Amit covers:

• How BlueRock Therapeutics is translating the promise of cell therapy into real clinical trials for Parkinson’s disease, and why this moment is so significant for patients who have exhausted existing treatments (01:09)

• What it takes to balance bold scientific vision with realism, credibility, and execution when leading clinical programmes at a pivotal stage (03:29)

• The real differences between CEO and CMO roles, why leadership is not about hierarchy, and how self-awareness shapes long-term career impact (04:58)

• Why authenticity, diversity of thought, and culture consistently separate successful biotechs from those that struggle, more than metrics alone (06:37)

• Lessons from a career spanning programmes such as Plavix and Spinraza at Biogen, and what physician scientists should consider when transitioning into industry roles (12:00)

If you want to understand how science, leadership, and empathy come together to shape medicines that can truly change lives, this is an episode worth your time.

Check out the full conversation and hear directly from one of the industry’s most thoughtful clinical leaders.

Follow ARTO: https://linktr.ee/arto_talent

Amit Rakhit

LinkedIn: https://www.linkedin.com/in/amit-rakhit/

Lawrence Rose

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Introduction and background

01:09 Cell therapy and BlueRock Therapeutics’ mission

03:29 Leadership, credibility, and execution

04:58 CEO vs CMO roles in biotech

06:37 Authenticity, inclusion, and culture

09:24 What separates successful biotechs

12:00 Physician scientists transitioning into industry

18:34 Career-defining moments and resilience

22:38 The future of cell therapy and emerging modalities

24:32 AI in drug discovery and clinical development

26:26 Closing thoughts and where to connect

#LeadingBeyondTheLab #ARTOTalent #CellTherapy #BiotechLeadership #RegenerativeMedicine #LifeSciences #ClinicalDevelopment

Hosted on Acast. See acast.com/privacy for more information.

What does it really take to back and build world-class biotech companies from idea to FDA approval?

This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital.

With over 20 years' experience spanning biotech investment, company creation, board leadership, and early-stage venture building, Jonathan has played a key role in building and scaling biotech companies across Europe, Australia and the US.

In this episode Jonathan covers:

- How Brandon Capital was co-founded in Australia by Chris Nave and Stephen Thompson, who grew it into a globally respected life sciences VC firm spanning company creation, long-term funding, and expansion in the US and UK.

- Jonathan reflects on how Brandon Capital has helped shape the Australian biotech ecosystem over the last almost 2 decades.

- Investments like AstronauTx, AdvanCell, Myricx Bio, and the stories from the frontline, including strategic pivots, tough decisions, successful exits, and the high-conviction bets that shaped portfolio outcomes.

- Practical, investor-led advice for founders raising venture capital; covering readiness, storytelling, common mistakes, and how to stand out in competitive funding rounds.

- How CatalYm has progressed deep into the clinic, and why Brandon Capital has supported the company through multiple funding rounds.

- Jonathan’s outlook on the future of biotech, from neuroscience and radiopharmaceuticals, to overlooked white-space opportunities shaping the next innovation cycle.

Be sure to check out the full episode of Leading Beyond the Lab, and don’t forget to like, subscribe, and share with anyone building in biotech.

To listen to (or watch) the full episode, search "Leading Beyond The Lab Jonathan Tobin" on your preferred streaming platform.

Hosted on Acast. See acast.com/privacy for more information.

This week on Leading Beyond The Lab, Lawrence Rose sat down with Nikhil Thatte, Partner at Lumira Ventures, a leading Canadian life sciences venture capital firm, with over a decade of experience backing transformative biotech and medtech companies across North America.

In this conversation, Nikhil shares how Lumira Ventures has built a top-quartile VC track record over multiple market cycles, investing across therapeutic areas including oncology, gene editing, gene therapy, immunology, cardiometabolic disease, and medical devices. He also reflects on his journey helping scale globally impactful healthcare companies while staying grounded in patient outcomes.

In this episode, Nikhil covers:

• How Lumira Ventures evaluates investment opportunities in today’s biotech market, including why clinical data, valuation discipline, and a clear path to liquidity now matter more than ever (08:38)

• Lessons from Lumira’s major exit successes, including Histosonics and Endotronix, and what made these companies stand out from an investor perspective, with insights into leadership, timing, and execution alongside Mike Blue at Histosonics (02:33)

• What truly differentiates exceptional founders and management teams, with real examples of conviction moments backing leaders such as Joanna Stanicka at Axonis and Jade Doucet-Martineau at Puzzle Med (22:08)

• Why Canada punches above its weight in life sciences innovation, the structural challenges holding the ecosystem back, and what must change to retain value domestically, including reflections on Canadian success stories discussed throughout the episode (17:40)

• The vision behind the Cancer Breakthrough Fund, Lumira’s partnership with the Terry Fox Foundation, and how this model brings new capital, clinical expertise, and impact-driven investors into oncology innovation (31:08)

If you want a rare, honest look inside how top life sciences VCs assess opportunity, leadership, and long-term value creation, this is an episode you don’t want to miss.

Follow ARTO: https://linktr.ee/arto_talent

Nikhil Thatte

LinkedIn: https://www.linkedin.com/in/nikhil-thatte-72372333/

Lawrence Rose

Director at ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Introduction to Nikhil Thatte and Lumira Ventures

02:33 Major exits including Histosonics and Endotronix

05:30 Fund V and what drives LP conviction today

08:38 How Lumira evaluates deals in the current biotech market

17:40 Canada’s competitive advantages and ecosystem challenges

22:08 Backing exceptional founders and leadership teams

31:08 The Cancer Breakthrough Fund and Terry Fox Foundation partnership

37:00 Technologies and trends shaping the next 5–10 years

41:16 Patient impact and what ultimately motivates long-term investing

#LeadingBeyondTheLab #ARTOTalent #LifeSciences #BiotechVC #Medtech #VentureCapital #CanadianInnovation

Hosted on Acast. See acast.com/privacy for more information.

This week on Leading Beyond The Lab, Lawrence Rose sat down with Jyothis George, CMO of Nodthera, and a global thought leader in the obesity space, shaping the future of cardio-metabolic and inflammatory disease innovation. Jyothis has led global programs across GLP-1, SGLT2, PCSK9 and now the emerging NLRP3 inhibitor class. His work spans companies such as Novo Nordisk, Amgen, Boehringer Ingelheim and his move into biotech with NodThera marks a shift from big-Pharma leadership into next-wave therapeutic development.

In this episode, Jyothis covers:

- How NodThera is shaping the future of metabolic and inflammatory disease treatment.

- A look at the mindset and challenges behind leading in a high-stakes biotech environment.

- Why the right investors often play a critical mentorship role in biotech growth.

- Exploring why endocrinology remains underfunded and overlooked in biotech circles.

- How he previously worked with Eli Lilly (led by David Ricks), contributing to their efforts in the cardiometabolic space.

- Reflections on personal legacy, long-term impact, and how to get in touch.

If you’re interested in cardio-metabolic innovation, GLP-1 evolution, biotech strategy or leadership at the cutting edge of science, this episode is worth your time.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Jyothis George

CMO at NodThera

LinkedIn: https://www.linkedin.com/in/jyothisgeorge/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

01:40 NodThera's Role in Future Endocrinology

10:48 Leadership in Biotech

21:05 Investment and Mentorship

30:58 Endocrinology's Underinvestment

38:13 Jyothis George: Legacy & Contact

Hosted on Acast. See acast.com/privacy for more information.

This week on Leading Beyond The Lab, @Lawrence Rose sat down with @Joey Mason, a venture investor with 25 years of experience across venture debt, venture capital and company building. Joey’s background spans senior roles with @Claret Capital Partners, @Sofinnova Partners, and earlier positions in investment banking and CRO services. His track record includes multiple successful exits, advising boards, working across Medtech, Biotech, digital health and Techbio, and supporting companies through regulatory approval, clinical development and commercial scale.

In this episode, Joey covers:

• Joey dives into his career spanning 25 years of Life Sciences experience, from early biotech to leading global investment firms.
• He unpacks the frameworks and philosophies that guide his investment decisions across the Life Sciences ecosystem.
• Joey reflects on a standout investment, what made it succeed, and the lessons it offers future founders.
• A candid discussion on what strong leadership looks like in high-growth Life Sciences ventures.
• Joey shares exactly what he looks for in a pitch, and what turns him off instantly.
• Looking ahead, Joey reveals where he’s placing bets and what excites him most about the next wave of Life Sciences innovation.

Check out this episode if you want a grounded, practical understanding of how life sciences companies are assessed, funded and supported behind the scenes, and how founders can communicate, hire and plan more effectively on the path to scale.

Follow ARTO!

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Lawrence Rose

Co-Founder + Talent Solutions Director at @ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Joey Mason

Venture Advisor @Sofinnova

Venture Partner @Claret Capital Partners

LinkedIn: https://www.linkedin.com/in/joey-mason/

Timestamps

01:09 Joey’s Career

05:14 Investment approaches

19:17 Most successful investment

28:20 Leadership

32:46 How to pitch to Joey Mason

42:21 Future plans

#LeadingBeyondTheLab #ARTOTalent #LifeSciences #VentureCapital #VentureDebt #Medtech #Biotech #TechBio #DigitalHealth #IrelandEcosystem #Pharma #InvestmentStrategy

Hosted on Acast. See acast.com/privacy for more information.

🎬 This week on Leading Beyond The Lab, Lawrence Rose sat down with Roel Bulthuis, Managing Partner and Head of Investments at Syncona Limited.

Roel has spent his career building, funding and scaling European biotech companies end-to-end, supporting high-performing teams from inception through clinical development, commercial launch and manufacturing scale-up.

Along the way he references outcomes from portfolio companies such as Autolus Therapeutics and Beacon Therapeutics, showing how patient capital and conviction-led strategy compound over time.

⭐️ Syncona has an impressive portfolio including,

Autolus Therapeutics, Beacon Therapeutics, Spur Therapeutics, iOnctura, Quell Therapeutics, ANAVEON AG, MOSAIC THERAPEUTIC SERVICES, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics.

🚀 In this episode, Roel dives into:

- What defines a Syncona company and its unique model

- Key lessons learned from both successes and setbacks

- How to manage investor involvement without stifling progress

- The challenges of leadership transitions within portfolio companies

- Syncona’s strategic commitment to the European market

- What drives Roel personally and what he enjoys most about his role

Check out this episode if you want grounded insight into biotech venture building, long-term capital strategy and how scientific founders scale from the lab to patient impact. 🤝

Follow ARTO!

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Lawrence Rose

Co-Founder + Talent Solutions Director at @ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Role Bulthuis

Managing Partner @Syncona

LinkedIn: https://www.linkedin.com/in/roel-bulthuis-aa414a/

Timestamps:

01:10 What makes up a Syncona company?

11:25 What were the main lessons learnt from previous failures/successes?

15:06 Managing investor involvement & preventing counter productivity.

22:14 The issues with exchanging leadership.

31:07 Commitment to the European Market.

42:20 What Roel enjoys about his job.

Hosted on Acast. See acast.com/privacy for more information.

This week, in one of our biggest episode of Leading Beyond the Lab yet, we sit down with Christophe Bourdon, CEO of LEO Pharma, a company valued in the multi-billion-euro range and entering one of the most defining chapters in its 100-year history.

With over 25+ years of global biopharma leadership experience, spanning pivotal roles at Amgen, Sanofi, and Orphazyme, Christophe brings a rare combination of commercial excellence, turnaround leadership, and global market insight. He also shares how senior leaders such as Murdo Gordon helped shape his approach to building high-performing, people-centric teams.

In this episode, Host of Leading Beyond The Lab, @Lawrence Rose, discusses with Christophe how he’s reshaping a century-old European company into a modern, innovation-driven global leader, covering:

1. Transforming LEO Pharma, from financial urgency to sustainable growth, cultural renewal, and long-term clarity.
2. The Partner and Development model, and why global players like Gilead Sciences and Boehringer Ingelheim have chosen LEO as a trusted innovation partner.
3. Leadership and culture at scale, transparency, conviction, rebuilding confidence, and empowering bold talent.
4. Preparing for a future IPO, aligning profitability, growth, and a clear 5-year vision for employees, shareholders, and partners.
5. Europe vs. the US in the next decade of biotech, why the US has become LEO’s largest affiliate and what this shift means for global competitiveness.

This episode is a rare look at what it truly takes to modernise a legacy company while keeping innovation, collaboration, and leadership at the core.

Be sure to check out this episode - one of our most important conversations to date.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Christophe Bourdon

CEO of LEO Pharma

LinkedIn: https://www.linkedin.com/in/christophe-bourdon-77a62b6/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 LEO’S Recent Achievements

06:58 Shaping a Modern LEO Pharma

16:30 LEO Pharma’s IPO Journey

25:39 Christophe’s Leadership

Hosted on Acast. See acast.com/privacy for more information.

This week we sit down with Clare Terlouw, Head of LifeArc Ventures, whose 20+ year career spans investment banking, biotech company building, and leading venture teams focused on health innovation. With a unique perspective at the intersection of science, capital, and patient impact, Clare shares a candid and optimistic view of the evolving biotech landscape in the UK and beyond.

In this episode, Clare covers:

- LifeArc Ventures’ mission: how a medical charity is driving returns while staying true to a patient-first vision.

- Investing and scaling biotech: from early inflection points to Series B and beyond, what great companies get right.

- Biotech in the UK: challenges in the current funding environment, the talent surge, and why optimism still holds.

- Tech-enabled drug discovery: how AI, computational biology, and new business models are shaping investment priorities.

- Clare's leadership lens: her personal drive, how she evaluates opportunity, and the power of staying focused on patient outcomes.

Be sure to check out this episode if you're interested in the future of biotech investing, the rise of tech-enabled therapeutics, and how one venture leader is backing science that matters.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Clare Terlouw

Managing Partner at Life Arc

LinkedIn: https://www.linkedin.com/in/clare-terlouw-b608aa17/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Life Arc - Investments + Impact

09:44 Investing in and Growing a Company

17:52 Biotech in the UK

26:18 Tech Enabled Drug Discovery

32:57 Clare Terlouw

Hosted on Acast. See acast.com/privacy for more information.

This week, we sit down with Dr. Danielle Meyrick, Director and Co-Founder at EPIC Theranostics, to explore the meteoric rise of nuclear medicine and radiotheranostics. With over 20 years of experience spanning academia, biotech, and hospital environments, Danielle is uniquely positioned as both a scientific pioneer and commercial strategist. Her career has spanned from launching radiopharmaceutical therapies in hospitals to shaping global strategies for biotech companies. If you're serious about understanding the future of oncology, this is the episode to watch. In this episode we cover:

• Why nuclear medicine is having a moment - and what makes radiotheranostics the most promising modality in oncology today.
• From PhD to MD – Danielle’s unconventional path to medicine, and how her dual perspective shaped her leadership style.
• What it takes to commercialise complex therapies – lessons from inside large pharma, mid-stage biotechs, and early-stage ventures.
• The clinical data that changed everything – and how early adopters leveraged compassionate use to gain momentum.
• What’s next for EPIC Theranostics – and why workforce readiness and isotope supply could make or break the sector.

If you're in biotech, pharma, or medtech, this episode is a masterclass in strategic thinking and scientific depth. Watch now and get ahead of where oncology is going.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Danielle Meyrick

Co-Founder + Director At EPIC Theranostiocs

LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

06:12 Nuclear Medicine

09:26 Characteristics of a Good Drug Developer

14:13 Future of Radiotheranostics

20:05 Approaching Challenges

26:52 Advice

29:25 Motivations

30:56 Greatest Achievements

#LeadingBeyondTheLab #ARTOTalent #Biotechnology 

Hosted on Acast. See acast.com/privacy for more information.

Dr. Rachel Humphrey (CEO) and Dr. Melinda Merchant (CMO) of Normunity are two of the most seasoned and respected leaders in oncology drug development, with a combined 45+ years of experience across big pharma, biotech, and translational science. Rachel led the development of Yervoy® (ipilimumab) at BMS, Imfinzi® (durvalumab) at AstraZeneca, and Nexavar® (sorafenib) at Bayer, before holding CMO roles at Black Diamond, Mirati, and CytomX. Melinda, an immunologist and dual board-certified pediatric oncologist, spent a decade leading clinical studies at NIH and Memorial Sloan Kettering, running early trials of ipilimumab, nivolumab, and novel cell therapies before moving to industry and leading clinical development efforts of multiple investigational new drugs. Together, they now lead Normunity, where they’re pioneering a bold new therapeutic category: immune normalizers - designed to unlock immune resistance and open up new frontiers in cancer treatment.In this episode, we cover:

- How Normunity is redefining immuno-oncology with its first-in-class T-cell engager

- What it takes to build scientific teams that challenge each other - and still move fast

- Lessons from launching Yervoy, Imfinzi, Tazverik, and other breakthrough therapies

- Why biotech culture needs both humility and ego to succeed

- What’s next as Normunity prepares to enter the clinic with NRM-823

If you're a life sciences leader, founder, or investor - this conversation is essential listening. Tap in to hear what it really takes to build, lead, and scale science that matters.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Rachel Humphrey

CEO at Normunity

LinkedIn: https://www.linkedin.com/in/rachel-w-humphrey-md-116b211b/

Melinda Merchant

CMO at Normunity

LinkedIn: https://www.linkedin.com/in/melinda-merchant-7b496a/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

16:58 Traits of a Drug Developer

19:53 Leadership in Biotech

27:28 Story Behind Normunity

30:23 Normunity Culture

32:28 Mindsets in Translational Science

36:33 Personal Life

#LeadingBeyondTheLab #ARTOTalent #Biotechnology

Hosted on Acast. See acast.com/privacy for more information.

In this episode, we cover:

• How Maxion is building a new therapeutic modality using KnotBody technology to tackle autoimmune and inflammatory diseases
• Why conviction, speed, and storytelling are non-negotiable in translational drug development
• Lessons from Genentech, MorphoSys, and Kymab on building pipelines, teams, and partnerships
• What investors really look for - and how Maxion secured a competitive Series A in a tough market
• How to hire and scale for scientific excellence without losing agility or collaboration

Tune in for a dynamic, insightful conversation with one of biotech’s most experienced and thoughtful leaders.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Arndt Schottelius

CEO at Maxion Theraprutics

LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

06:46 Translational Science

08:55 Lessons in Biotech Leadership

25:23 Maxion - Culture and Roundup

#LeadingBeyondTheLab #ARTOTalent #Biotechnology 

Hosted on Acast. See acast.com/privacy for more information.

Dr. Christopher Morabito, Chief Medical Officer at Astria Therapeutics, joins us to share hard-won lessons from 25 years in rare disease, oncology, and immunology. But this isn’t a career retrospective - it’s a deep dive into the mindset, strategies, and leadership habits that drive biotech success.

In this episode, Chris reveals:

• How to make tough go/no-go decisions when the data isn’t clear.
• The leadership traits that keep teams aligned, motivated, and resilient in high-pressure environments.
• Why clarity of purpose matters more than anything else in a biotech’s mission.
• How to navigate the tension between scientific ambition and commercial reality.
• The patterns he’s seen across programs that make it from idea to approval.

Chris distills decades of experience into practical, actionable advice for founders, executives, and investors - making this one of the most insightful conversations we’ve had yet.

🎧 Tune in for a rare, candid look at biotech leadership from someone who’s been on the front lines of game-changing therapies.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Christopher Morabito

CMO at Astria Therapeutics

LinkedIn: https://www.linkedin.com/in/chrismorabito/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

13:40 Moving Into Biotech

23:34 Leading in Biotech

28:41 Patients First

38:23 Lessons & Legacy

#LeadingBeyondTheLab #ARTOTalent #Biotechnology 

Hosted on Acast. See acast.com/privacy for more information.

We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene.

In this episode, Bhaskar dives deep into:

· How Triveni is building a first-in-class pipeline targeting the kallikrein system - a bold bet to treat severe skin and inflammatory conditions by tackling novel biology.

· What it means to be a founder’s CMO, and how great science needs the right development strategy to make a difference.

· Candid stories from his past roles at Nimbus (which sold its TYK2 program to Takeda for $4B) and Janssen, where he helped guide first-in-class therapies from Phase 1 to pivotal trials.

· Why bispecifics may be risky but worth it, and how Triveni is using novel biologics to crack tough diseases like atopic dermatitis.

· Advice for executives: how to balance ambition and discipline, when to say no, and why choosing the right team members matters as much as the science.

🎙 Bhaskar doesn’t just talk science - he connects molecular biology to patient need, clinical strategy, and company vision with clarity and purpose.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Bhaskar Srivastava

CMO at Triveni Bio

LinkedIn: https://www.linkedin.com/in/bhaskar-srivastava-355a9ab1/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

15:44 Success & Growth in Biotech

28:43 Investing in Biotech

34:23 The Future of Dermatology & Triveni Bio

#LeadingBeyondTheLab #ARTOTalent #Biotechnology 

Hosted on Acast. See acast.com/privacy for more information.

We’re joined by Mara Aspinall, Partner at Illumina Ventures, a trailblazer with over 30 years of leadership in diagnostics and eight years in venture capital funding groundbreaking genomics companies.

In this episode, Mara reveals:

• The next wave of diagnostics, from liquid biopsies to home testing and new AI-driven tools.
• Hard-won lessons from leading Genzyme Genetics, Roche Tissue Diagnostics, and building her own startup.
• Insider tips for founders on pitching, choosing the right investors, and building winning teams.
• A glimpse into where genomics is heading in the next decade - from neurodegenerative disease detection to early metabolic disease diagnostics.

With her unmatched experience as an operator, educator, and investor, Mara brings clarity, energy, and vision to a fast-changing field. This conversation is packed with takeaways for founders, investors, and anyone fascinated by the future of healthcare.

🎧 Tune in now for a masterclass in diagnostics, genomics, and venture capital from one of the industry’s most influential voices.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Mara Aspinall

Partner At Illumina Ventures

LinkedIn: https://www.linkedin.com/in/mara-aspinall-6688142/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

04:10 Current Diagnostic Trends

20:48 The Founder Investor Fit

25:37 Genetics & Genomics

29:06 Mara Aspinall

39:31 Neurodegenerative Disease

#LeadingBeyondTheLab #ARTOTalent #Biotechnology 

Hosted on Acast. See acast.com/privacy for more information.

In this episode, we’re joined by Dr. Sascha Berger, a biotech investment director based in Saudi Arabia and a very experienced life science investor globally. With nearly two decades in the industry, he’s seen breakthroughs, pivots, and billion-dollar transactions.

He reveals:

• Saudi Arabia’s high-stakes plan to become a global biotech superpower by 2040 - and why it could disrupt the industry as we know it.
• The real role of a VC beyond the money - how top investors become game-changing partners for founders.
• Raw stories from the front lines - startups on the brink of collapse that fought back to success.
• No-fluff advice for first-time founders on building the right team and surviving the brutal biotech rollercoaster.
• A global insider’s view on the next wave of innovation - from Boston’s biotech streets to the Middle East’s rising hubs.

This is one of our most unfiltered and insightful episodes yet - a must-watch for founders, investors, or anyone who wants to see where life sciences is really heading.

🎧 Tune in now to hear how a leading investor is driving biotech’s next era.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Sascha Berger

Saudi Arabia Biotech Investor

LinkedIn: https://www.linkedin.com/in/sasber/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

08:04 Investing in Success

26:13 Saudi Arabia - The Future

36:29 How to Secure Investment

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology

Hosted on Acast. See acast.com/privacy for more information.

• Dr. Maeda-Chubachi serves as fractional Chief Medical Officer at various startups focusing on dermatology indications.
• 20+ years experience in the pharmaceutical industry, Dr. Maeda-Chubachi has held senior roles at major companies like Pfizer, Eli Lilly, and GSK. Her expertise spans the entire drug development process, from early-phase trials to regulatory approvals.
• Tomoko has multiple notable achievements, she led the FDA approval of Zelsuvmi, helped secure a $250M deal for Vtama, and was named one of 2023’s top CMOs to watch.
• Dr. Maeda-Chubachi is a sought-after speaker, having presented at events like the Dermatology Drug Development Summit and the Japan Biotech Panel. She is also an active member of Women In Bio, receiving the Long Tenure Active Member Award from the RTP chapter.

In this episode, we discuss a range of topics, including her career beginnings, challenges that come with drug development, leadership in biotech, key achievements and much more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Tomoko Maeda-Chubachi

CMO at Kalm Therapeutics + Boardroom Ready at Women in Bio

LinkedIn: https://www.linkedin.com/in/tomoko-maeda-chubachi/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

06:23 Drug Development

08:59 Leadership

13:58 Achievements + Fractional CMO

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology

Hosted on Acast. See acast.com/privacy for more information.

• Nick is the Founder & CEO at Alpenglow Biosciences, pioneers in AI-powered 3D spatial biology that transforms how we see and understand tissue biopsies.
• 10+ years in translational research, with degrees in biochem, epidemiology, and medicine – plus a residency and fellowship in pathology at the University of Washington.
• Co-developed a groundbreaking open-top light-sheet microscope – now the core of Alpenglow’s tech.
• Nick is a major conference speaker at AACR, SID, PMWC, NextGen Omics, BIO International and more, and has won the Castleman Award - the highest global honour for pathologists under 40.

In this episode, we discuss a range of topics including Alpenglow’s current success and what the future looks like, hiring talent within techbios, as well and leadership challenges within the computational biology space. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Nicholas Reder

Founder + CEO at Alpenglow Biosciences

LinkedIn: https://www.linkedin.com/in/nicholas-reder-210a578b/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings & Alpenglow

04:54 AI & Hiring Talent

14:58 Challenges / Key Triggers When Hiring

19:36 Alpenglow Biosciences

24:14 What’s Next - Quickfire Round

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology

Hosted on Acast. See acast.com/privacy for more information.

• Bernardo is the Co-Founder and COO of Concerto Biosciences, a biotech pioneering the development of microbial consortia-based therapeutics.
• With a robust background in microbial engineering, Bernardo has dedicated his career to studying microbial interactions and microbiome health. His expertise spans sythetic biology and metabolic engineering.
• Bernardo is internationally recognised for his contributions to microbiome science, particularly in translating complex microbial ecology into practical applications. His work at Concerto Biosciences has positioned him as a thought leader in developing next-generation microbial therapeutics.
• Prior to co-founding Concerto Biosciences, Bernardo earned his PhD in Microbiology from the Massachusetts Institute of Technology (MIT).
• Concerto has been active at major scientific conferences, including the 2024 BIO International Convention, where Concerto Biosciences was featured in the NIH Innovation Zone.

In this episode, we discuss the future of microbiome sciences, Bernardo’s key learnings throughout his career, how he’s adapted his leadership as one of three Co-Founders, management, a great opportunity within the market and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Bernardo Cervantes

Chief Operations Officer at Concerto Biosciences

LinkedIn: https://www.linkedin.com/in/bernacularbio/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings & Concerto Biosciences

10:16 Concerto Biosciences - Key Learnings

15:26 Team Building & Culture

23:52 Quickfire Questions

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology

Hosted on Acast. See acast.com/privacy for more information.

• CEO of Arcutis Biotherapeutics, one of the few commercial stage Dermatology focused Biopharma companies; leading them from startup to IPO to commercial success.
• 25+ years in biotech and pharma with expertise across of various Therapeutic areas.
• Proven leader in life sciences, known for building and scaling companies from early-stage to FDA approval - with leadership forged from time spent in the U.S. Navy.
• Former roles at Kythera, Lilly Amgen, and Allergan - driving strategy, R&D, and game-changing product launches.
• Champion of innovation, access, and purpose-driven leadership across the biopharma ecosystem

In this episode, we discuss everything from How Frank built Arcutis, motivation and Self-Improvement that is grounded from his experience in the Navy, revealing the key to success as a leader in the industry. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Frank Watanabe

President, CEO At Arcutis

LinkedIn: https://www.linkedin.com/in/frank-watanabe-419711/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings + Arcutis

05:01 Leadership & Growth

20:52 Motivation & Self Improvement

27:40 Personality Traits To Succeed In Pharma

33:30 What’s Next For Arcutis

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology

Hosted on Acast. See acast.com/privacy for more information.

• CMO at Almirall, a global pharmaceutical company specialising in medical dermatology, dedicated to developing innovative treatments for skin diseases.
• 20+ years of experience in dermatology, bridging between R&D, business development, marketing, and sales.
• Recognised globally for his commitment to understanding patient needs and demonstrating the real-world value of medicines.
• Former roles at Celgene, GlaxoSmithKline, Pfizer, Servier and Boehringer Ingelheim, leaving Volker with the experience to lead and scale cross-functional teams ensures the seamless integration of regulatory, clinical, and commercial strategies.
• Volker recently contributed to Almirall’s 15th annual Skin Academy, a conference that brings together dermatologists from across Europe to discuss advancements in inflammatory skin diseases and patient well-being.
• 
  

In this episode, we discuss the future of dermatology, Volker’s insights from industry roundtables, and the key experiences and achievements that shaped his success in the field. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Volker Koscielny

Chief Medical Officer at Almirall

LinkedIn: https://www.linkedin.com/in/volker-koscielny/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Leadership In Life Sciences

10:40 Potential In Dermatology

16:21 Functionality As A Leader

22:40 Achievements & Wrapping Up

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology

Hosted on Acast. See acast.com/privacy for more information.

• Co-Founder at Alys Pharmaceuticals, a biopharmaceutical company with an innovation focus on immuno-dermatology, redefining how we understand chronic itch and skin inflammation. Brian is also the Director of the Mark Lebwohl Center for Neuroinflammation and Sensation and the Allen Discovery Center for Neuroimmune Interactions.
• Sol and Clara Kest Professor and Vice Chair of Research in Dermatology at Icahn School of Medicine at Mount Sinai.
• Nearly two decades of experience spanning dermatology, immunology, allergy and neuroscience.
• Internationally recognised for unlocking the mysteries of itch biology, opening doors to entirely new therapeutic approaches.
• Previously the Co-Founder of Nuogen Pharma and now on the scientific advisory board for Attovia Therapeutics and Triveni Bio. Brian is also an advisor for Septerna - helping to translate scientific insights into next-generation therapies.
• Recent keynote speaker at the prestigious Friedman Brain Institute’s Neuroscience Retreat, as well as plenary talks across both allergy and dermatology like the American Academy of Allergy, Asthma, and Immunology (AAAAI) Presidential Plenary Session (2/23/2024) and the Marion B. Sulzberger, MD Memorial Award and Lectureship at the American Academy of Dermatology March of 2024 - proving how his work resonates across disciplines.

In this episode, we discuss everything from Innovation & AI in dermatology to Leadership in Academia vs Industry. Brian also reveals the reason Dermatology is securing so much funding in 2025. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Brian Kim

Co-Founder At Alys Pharmaceuticals

LinkedIn: https://www.linkedin.com/in/brian-s-kim-4605662/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Innovation & AI

11:08 Communication & Motivation

23:58 Leadership in Industry VS Academia

35:32 Why Dermatology Secures Funding

49:29 Quickfire Questions

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology #Immunology

Hosted on Acast. See acast.com/privacy for more information.

Juergen is the Founder & CEO of MoglingBio Inc, an innovative company in the longevity space, pioneering novel pharmacological approaches to rejuvenate old stem cells, a field with immense potential. As well as this, Juergen is also the Fractional CMO of SciRhom, a Munich-based clinical-stage biotech tackling autoimmune diseases with iRhom2-targeting therapies, where they have just secured a €63M Series A funding round to propel their groundbreaking work.

In this insightful conversation, we explore, how Juergen kick-started his career in life sciences, how he kept his career "fresh" in a big pharma setting by taking on new challenges, the challenges and adaptions from transitioning from big pharma to biotech, lessons from founding and funding his own biotech ventures, what "Longevity" really means in the biotech world, how he adapts across various therapeutic areas and much more.

This episode is packed with valuable insights for anyone in life sciences, whether you're a scientist, entrepreneur, investor, or industry leader. Don't miss this inspiring discussion on innovation, adaptability, and leadership in biotech!

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Juergen Reess

LinkedIn: https://www.linkedin.com/in/juergen-reess-b443468/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

10:23 Shifting to Biotech

16:13 Founding a Biotech

21:15 Communicating with Investors

24:41 AI in Life Sciences

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Neurology

Hosted on Acast. See acast.com/privacy for more information.

We discuss a variety of topics including Ingmar’s successes and mistakes, drug development, golden rules for biotechs, as well as fundraising in the life science industry. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Ingmar Bruns

LinkedIn: https://www.linkedin.com/in/ingmar-bruns-9abb5446/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

12:12 Key Accomplishments and Reflections

20:50 Persistence in Drug Development

27:52 Identifying Differentiators in Biotechs

38:00 Communicating with Investors

53:17 Traits of Effective Leadership

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Hematology

Hosted on Acast. See acast.com/privacy for more information.

Dr. Christophe Giot delivers a combination of stories and insights, including discussion on soft skills, communicating with investors, team building, AI in Pharma, the power of networking, onboarding, and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Cristophe Giot

LinkedIn: https://www.linkedin.com/in/christophegiot/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

08:03 Transitioning to Industry

14:27 Communicating with Stakeholders

16:36 The Role of AI in Pharma

19:19 Hiring and Onboarding Best Practices

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Cardiology

Hosted on Acast. See acast.com/privacy for more information.

Dr. Tusche reveals an amazing blend of experiences and advice, featuring discussions of early investment, oncology, micromanagement, addiction, ChatGPT, and obesity. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Dr. Micheal Tusche

LinkedIn: https://www.linkedin.com/in/vcbiotechceo/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

08:12 Investing In & Leading Biotech Companies

14:44 Differentiators in Biotech Success

24:42 Trends in Biotechs

36:45 Building Optimised Teams in Biotechs

45:06 Quick-fire Round

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology

Hosted on Acast. See acast.com/privacy for more information.

Dr. Chadha delivers a combination of advice and stories, including discussion on Regulation vs Drug Development, delegation, Antonella’s experience at TEDx, AI becoming Doctors, Alzheimer’s, the Women’s Brain Foundation, Medical Affairs and Clinical development working hand in hand and a lot more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Dr. Antonella S. Chadha

LinkedIn: https://www.linkedin.com/in/dr-antonella-santuccione-chadha-6336b41/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

11:00 Regulatory Hurdles in Drug Development

14:23 Academia/ Hospital to Industry

23:20 Longevity: A Complex Landscape

28:49 Communicating with Investors

32:56 AI in the Future

38:33 Embracing Change in Career Transitions

44:37 The Women’s Brain Foundation

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology

Hosted on Acast. See acast.com/privacy for more information.

Dr. Kharabi unveils a mix of stories and insights, including discussions about biotech success and failure, communicating with investors, recruitment in life sciences, how AI is being using in drug development, recent oncology discovery and more. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Youtube: ARTO Recruitment

Website: Home

Dr. Behzad Kharabi

LinkedIn: https://www.linkedin.com/in/behzadkharabi/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

12:08 Advice for Moving Into Industry

16:38 Key Learnings for Leaders

29:41 AI’s Future in Drug Development

#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Oncology #Hematology

Hosted on Acast. See acast.com/privacy for more information.